Thymosin Alpha 1 Trial Aims to Prevent Organ Failure After Aortic Dissection Surgery

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are severe, life-threatening complications and the major causes of death in patients suffering from acute aortic syndrome (AAS), a critical condition involving sudden damage to the aorta. Preventing these devastating post-operative complications holds substantial clinical value, and immunomodulatory therapy with thymosin alpha 1 (a naturally occurring peptide with immune-modulating properties) is hypothesized to be beneficial. This study was specifically designed to test the hypothesis that thymosin alpha 1 administration during the acute phase of AAS will result in a reduced incidence of SIRS and MODS, thereby improving patient prognosis.